MX2022012707A - Metodos de tratamiento del sindrome respiratorio agudo grave. - Google Patents

Metodos de tratamiento del sindrome respiratorio agudo grave.

Info

Publication number
MX2022012707A
MX2022012707A MX2022012707A MX2022012707A MX2022012707A MX 2022012707 A MX2022012707 A MX 2022012707A MX 2022012707 A MX2022012707 A MX 2022012707A MX 2022012707 A MX2022012707 A MX 2022012707A MX 2022012707 A MX2022012707 A MX 2022012707A
Authority
MX
Mexico
Prior art keywords
methods
acute respiratory
respiratory syndrome
treatment
severe acute
Prior art date
Application number
MX2022012707A
Other languages
English (en)
Spanish (es)
Inventor
Adrian Hepner
Original Assignee
Eagle Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eagle Pharmaceuticals Inc filed Critical Eagle Pharmaceuticals Inc
Publication of MX2022012707A publication Critical patent/MX2022012707A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2022012707A 2020-04-10 2021-04-08 Metodos de tratamiento del sindrome respiratorio agudo grave. MX2022012707A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063008529P 2020-04-10 2020-04-10
US202063062623P 2020-08-07 2020-08-07
PCT/US2021/026303 WO2021207444A1 (en) 2020-04-10 2021-04-08 Methods of treating severe acute respiratory syndrome

Publications (1)

Publication Number Publication Date
MX2022012707A true MX2022012707A (es) 2023-01-05

Family

ID=75690705

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012707A MX2022012707A (es) 2020-04-10 2021-04-08 Metodos de tratamiento del sindrome respiratorio agudo grave.

Country Status (11)

Country Link
US (1) US12582633B2 (https=)
EP (1) EP4132516A1 (https=)
JP (1) JP2023521162A (https=)
KR (1) KR20220167292A (https=)
CN (1) CN115916189A (https=)
AU (1) AU2021254415A1 (https=)
BR (1) BR112022020107A2 (https=)
CA (1) CA3174684A1 (https=)
IL (1) IL296518A (https=)
MX (1) MX2022012707A (https=)
WO (1) WO2021207444A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12605364B2 (en) * 2020-04-10 2026-04-21 Eagle Pharmaceuticals, Inc. Methods of treating SARS-CoV-2 infections

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY201417A (en) 2017-10-20 2024-02-21 Eagle Res Labs Limited Dantrolene prodrugs and methods of their use
US11123328B2 (en) 2017-11-14 2021-09-21 University Health Network Dantrolene and analogs thereof for the chronic treatment and prevention of dyssynchronous cardiac dysfunction
WO2019175761A1 (en) 2018-03-12 2019-09-19 Orbicular Pharmaceutical Technologies Private Limited Ready to use dantrolene compositions
US12246028B2 (en) 2018-11-27 2025-03-11 Eagle Research Labs Limited Use of dantrolene and dantrolene prodrugs to treat radiation exposure
US12605364B2 (en) 2020-04-10 2026-04-21 Eagle Pharmaceuticals, Inc. Methods of treating SARS-CoV-2 infections

Also Published As

Publication number Publication date
US12582633B2 (en) 2026-03-24
EP4132516A1 (en) 2023-02-15
WO2021207444A1 (en) 2021-10-14
CA3174684A1 (en) 2021-10-14
AU2021254415A1 (en) 2022-10-20
US20230149363A1 (en) 2023-05-18
IL296518A (en) 2022-11-01
CN115916189A (zh) 2023-04-04
BR112022020107A2 (pt) 2022-11-29
KR20220167292A (ko) 2022-12-20
JP2023521162A (ja) 2023-05-23

Similar Documents

Publication Publication Date Title
CL2019003126A1 (es) Métodos de tratamiento mediante el uso de un compuesto inhibidor de jak.
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
MX2022000271A (es) Inhibidores de la quinasa progenitora hematopoyetica 1 y usos de los mismos.
CL2020002512A1 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak.
MX2022000143A (es) Metodos novedosos.
MX2024002538A (es) Uso de un inhibidor de la ezh2 en la preparacion de farmacos para el tratamiento del linfoma de linfocitos t.
AR117920A1 (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
MX2019015207A (es) Compuestos para tratar el cancer de ovario.
MX2020010697A (es) Kit, composicion y terapia de combinacion para el sindrome del cromosoma x fragil.
MX2021013980A (es) Compuesto para el tratamiento de gota o hiperuricemia.
AR112144A1 (es) Compuestos para el tratamiento del sarcoma
NI201800083A (es) Procedimiento para el tratamiento y la profilaxis de vih y sida
MX2024002581A (es) Lou064 para el tratamiento de la esclerosis multiple.
CL2022003039A1 (es) Inhibidores de il4i1 y métodos de uso.
CL2022001353A1 (es) Inhibidores de egfr
MX2021012824A (es) Métodos para tratar el prurito.
EA201990109A1 (ru) Митохондриальные ингибиторы для лечения пролиферативных нарушений
CO2023017669A2 (es) Terapia combinada anti-vhc ventajosa
MX2022012707A (es) Metodos de tratamiento del sindrome respiratorio agudo grave.
AR122933A1 (es) Métodos para tratar la enfermedad cardiovascular
AR128711A1 (es) Métodos para tratar carcinoma microcítico de pulmón
MX2021014523A (es) Metodos para tratar colangiocarcinoma.
CO2025006782A2 (es) Composición farmacéutica para la prevención o tratamiento contra úlcera péptica relacionada a fármacos, que comprende zastaprazán o una sal farmacéuticamente aceptable del mismo
AR131842A1 (es) Métodos para tratar gliomas
AR099416A1 (es) Terapia combinada para la hipertensión resistente